https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-24 / J Extracell Vesicles 2013;2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-24 / J Extracell Vesicles 2013;22013-10-24 00:00:002019-02-15 08:46:15Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-21 / Neurol. Med. Chir. (Tokyo) 2013;53(11):741-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-21 / Neurol. Med. Chir. (Tokyo) 2013;53(11):741-542013-10-21 00:00:002019-02-15 08:47:29Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-04 / Expert Rev Vaccines 2013 Oct;12(10):1195-210
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-04 / Expert Rev Vaccines 2013 Oct;12(10):1195-2102013-10-04 00:00:002019-02-15 08:39:48Exploiting dendritic cells in the development of cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-01 / Immunotherapy 2013 Oct;5(10):1039-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-01 / Immunotherapy 2013 Oct;5(10):1039-422013-10-01 00:00:002019-02-15 08:50:41Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-01 / BioDrugs 2013 Oct;27(5):453-68
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-01 / BioDrugs 2013 Oct;27(5):453-682013-10-01 00:00:002019-02-15 08:39:51A review of dendritic cell therapy for cancer: progress and challenges
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-01 / Immunotherapy 2013 Oct;5(10):1043-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-01 / Immunotherapy 2013 Oct;5(10):1043-62013-10-01 00:00:002021-11-15 14:42:34Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-01 / Cancer Immunol Res 2013 Oct;1(4):210-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-01 / Cancer Immunol Res 2013 Oct;1(4):210-62013-10-01 00:00:002019-02-15 09:18:14Temperature matters! And why it should matter to tumor immunologists
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-09-12 / J Extracell Vesicles 2013;2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-09-12 / J Extracell Vesicles 2013;22013-09-12 00:00:002013-09-12 00:00:00Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-09-11 / Mol. Cancer 2013 Sep;12(1):103
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-09-11 / Mol. Cancer 2013 Sep;12(1):1032013-09-11 00:00:002019-02-15 09:22:36Oncolytic viruses as therapeutic cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-09-01 / Colorectal Dis 2013 Sep;15(9):1107-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-09-01 / Colorectal Dis 2013 Sep;15(9):1107-142013-09-01 00:00:002019-02-15 08:39:14Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer
